Erectile Dysfunction Clinical Trial
Official title:
A Double-blind, Placebo-controlled, Parallel Design, Randomized, Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene Transfer in Males With Erectile Dysfunction
To evaluate the safety and efficacy of a single intracavernous injection of hMaxi K (8000 µg and 16000 µg) or placebo upon penile rigidity or erection in males with erectile dysfunction longer than six months that is attributable to an underlying, stable medical condition.
This study is a double-blind, placebo controlled, parallel design, Phase 2A study evaluating
the potential activity and safety of a single administration of hMaxi-K (8000 or 16000 µg) or
placebo (PBS sucrose 20%) injected into the corpus cavernosum of the penis in men who have
been unable to tolerate, do not wish to continue, or have had unsuccessful results with,
prior therapy for ED.
The study population is men with erectile dysfunction attributable to an underlying, stable
medical condition but who are otherwise in good health. The target population is men with
erectile dysfunction and those who have been unable to tolerate, do not wish to continue, or
have had unsuccessful results with, prior therapy for ED and with an erectile function domain
score of IIEF < 21 at screening and baseline.
Following screening and study drug administration at Week 0 (Visit 2 [V2]), eligible
participants will be evaluated at Weeks 1 (V3), 4 (V4), 8 (V5), 12 (V6), and 24 (V7). At each
study visit, participants will have a physical examination including examination of the penis
(all visits), vital signs, electrocardiogram (ECG) (all visits). Laboratory evaluations
including chemistry and hematology will be done at V1, V3, V4, V6, and V7. Urinalysis will be
done V1, V2 (prior to dosing), V3, V4, V6, and V7. Endocrine parameters and PTT, PT, sed rate
and CRP will be evaluated at V1, V3, and V7. The participant will complete the erectile
function domain of the IIEF and Sexual Encounter Profile (SEP) at screening/baseline and at
V2, (SEP and IIEF at V2 prior to dosing) V3, V4, V5, V6, and V7. In all participants, plasma
specimens will be collected to assay for the presence of hSlo DNA by PCR (V2-V7). These will
be kept frozen at -20°C or less at the site for eventual assay by Sponsor.
The primary efficacy outcome measures will include the Erectile Function (EF) domain of the
International Index of Erectile Function (IIEF), Sexual Encounter Profile (SEP), Questions 2
and 3 from SEP. The IIEF EF domain has a 30-point total score, where higher scores reflect
better erectile function. SEP is a diary in which participants record each sexual attempt
made throughout the study. The two questions from the Sexual Encounter Profile (SEP) deal
with the ability to achieve vaginal penetration (SEP2), and the ability to maintain an
erection long enough for successful intercourse (SEP3). The erectile function domain category
of the IIEF will be used to evaluate the change in erectile status from baseline following
administration of hMaxi-K. Change from baseline on the six questions of the IIEF's Erectile
function domain category at every visit after administration of study drug will be calculated
and compared among the two dose and one placebo groups.
Safety will be assessed by analysis of adverse experiences, and abnormal findings on clinical
laboratory tests, electrocardiogram, and physical examinations.
6 months per participant (approximately 2 years to enroll all participants)
A total of 35 participants were planned to be enrolled; N=11 on 8000 µg; N=11 on 16000 µg;
N=13 on placebo.
Both the safety data and data to assess activity will be presented as means and standard
deviations or medians and ranges as appropriate for continuous data, and analyzed using
either paired t- or Wilcox on Sign Rank tests for within group changes, and with mixed
effects or marginal models to determine differences in trends among the three cohorts over
time. Incidence of adverse events will be presented as relative frequencies within groups.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 | |
Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 |